353 related articles for article (PubMed ID: 32282230)
1. Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data.
Oh S; Geistlinger L; Ramos M; Morgan M; Waldron L; Riester M
JCO Clin Cancer Inform; 2020 Apr; 4():321-335. PubMed ID: 32282230
[TBL] [Abstract][Full Text] [Related]
2. PureCN: copy number calling and SNV classification using targeted short read sequencing.
Riester M; Singh AP; Brannon AR; Yu K; Campbell CD; Chiang DY; Morrissey MP
Source Code Biol Med; 2016; 11():13. PubMed ID: 27999612
[TBL] [Abstract][Full Text] [Related]
3. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.
Favero F; Joshi T; Marquard AM; Birkbak NJ; Krzystanek M; Li Q; Szallasi Z; Eklund AC
Ann Oncol; 2015 Jan; 26(1):64-70. PubMed ID: 25319062
[TBL] [Abstract][Full Text] [Related]
4. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
[TBL] [Abstract][Full Text] [Related]
5. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
Heydt C; Rehker J; Pappesch R; Buhl T; Ball M; Siebolts U; Haak A; Lohneis P; Büttner R; Hillmer AM; Merkelbach-Bruse S
Sci Rep; 2020 Jul; 10(1):11387. PubMed ID: 32647293
[TBL] [Abstract][Full Text] [Related]
6. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
[TBL] [Abstract][Full Text] [Related]
7. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.
Jang H; Choi CM; Lee SH; Lee S; Jeong MK
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723
[TBL] [Abstract][Full Text] [Related]
8. Sequential filtering for clinically relevant variants as a method for clinical interpretation of whole exome sequencing findings in glioma.
Ülgen E; Can Ö; Bilguvar K; Akyerli Boylu C; Kılıçturgay Yüksel Ş; Erşen Danyeli A; Sezerman OU; Yakıcıer MC; Pamir MN; Özduman K
BMC Med Genomics; 2021 Feb; 14(1):54. PubMed ID: 33622343
[TBL] [Abstract][Full Text] [Related]
9. A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast Cancer.
Kaur P; Campo D; Porras TB; Ring A; Lu J; Chairez Y; Su Y; Kang I; Lang JE
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650480
[TBL] [Abstract][Full Text] [Related]
10. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of copy number variation detection tools for cancer using whole exome sequencing data.
Zare F; Dow M; Monteleone N; Hosny A; Nabavi S
BMC Bioinformatics; 2017 May; 18(1):286. PubMed ID: 28569140
[TBL] [Abstract][Full Text] [Related]
12. Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer.
O'Brien TD; Jia P; Xia J; Saxena U; Jin H; Vuong H; Kim P; Wang Q; Aryee MJ; Mino-Kenudson M; Engelman JA; Le LP; Iafrate AJ; Heist RS; Pao W; Zhao Z
Methods; 2015 Jul; 83():118-27. PubMed ID: 25913717
[TBL] [Abstract][Full Text] [Related]
13. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
[TBL] [Abstract][Full Text] [Related]
14. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
15. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Vilimas T
Methods Mol Biol; 2020; 2055():63-91. PubMed ID: 31502147
[TBL] [Abstract][Full Text] [Related]
16. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
[TBL] [Abstract][Full Text] [Related]
17. Bamgineer: Introduction of simulated allele-specific copy number variants into exome and targeted sequence data sets.
Samadian S; Bruce JP; Pugh TJ
PLoS Comput Biol; 2018 Mar; 14(3):e1006080. PubMed ID: 29590101
[TBL] [Abstract][Full Text] [Related]
18. AbsCN-seq: a statistical method to estimate tumor purity, ploidy and absolute copy numbers from next-generation sequencing data.
Bao L; Pu M; Messer K
Bioinformatics; 2014 Apr; 30(8):1056-1063. PubMed ID: 24389661
[TBL] [Abstract][Full Text] [Related]
19. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
20. Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.
Chong ML; Knight J; Peng G; Ji W; Chai H; Lu Y; Wu S; Li P; Hu Q
Cancer Genet; 2023 Aug; 276-277():30-35. PubMed ID: 37418972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
